The Immunoassay Center has developed a new product to diagnose the Sars-Cov-2 virus.

Havana, Cuba.- Under the brand name Umelisa, after extensive tests, the kit will soon be integrated into the sanitary and virus detection protocols in Cuba.

According to a report by Cubavisión Internacional, the product was validated by the Pedro Kourí Institute of Tropical Medicine. The Center for State Control of Medicines, Equipment, and Medical Devices (CECMED), has already registered it.

According to Irina Valdivia Álvarez, deputy director of the Diagnostics Development and Production area, the test performed with this technology identifies the virus presence in asymptomatic suspect patients in just four hours.

She added that it is a 100% Cuban technology, both the kit and the raw materials used for its development and production.

Valdivia Álvarez said that its presence on the island’s health system would allow more than 705,000 diagnostic tests.

CUBA REPORTS 3,075 NEW CASES, 21 DEATHS

Cuban health authorities reported on Monday 3 705 new COVID-19 infections and 21 deaths associated with the disease.

The National Director of Epidemiology, Dr. Francisco Durán García, said that 19 113 confirmed patients with the virus remained hospitalized, and 3261 people were discharged.

Cuba now totals 207,322 people diagnosed with the disease and 1,372 fatalities since the beginning of the pandemic.

The territories with the most infections reported were Matanzas with 795, Havana 485, Santiago de Cuba 300, and Camaguey with 229 cases.

Meanwhile, six million 675 thousand 661 doses of Cuban vaccine candidates against Covid-19 were administered as of July 3.

Two million 869 thousand 501 people received at least one dose of one of the Cuban vaccine candidates; two million 196 thousand 863 people have already received a second dose, and one million 609 thousand 454 are fully vaccinated. (RHC)